Chennai Journal

Fanconi Anemia Pipeline and Clinical Trials Assessment (2023) | Companies – Rocket Pharmaceuticals, Foresee Pharmaceuticals, Elixirgen, Genethon, Spotlight Therapeutics, and others

 Breaking News
  • No posts were found

Fanconi Anemia Pipeline and Clinical Trials Assessment (2023) | Companies – Rocket Pharmaceuticals, Foresee Pharmaceuticals, Elixirgen, Genethon, Spotlight Therapeutics, and others

June 07
11:50 2023
Fanconi Anemia Pipeline and Clinical Trials Assessment (2023) | Companies - Rocket Pharmaceuticals, Foresee Pharmaceuticals, Elixirgen, Genethon, Spotlight Therapeutics, and others

DelveInsight’s report titled “Fanconi Anemia Pipeline Insight 2023” offers extensive information on more than 4+ companies and over 4+ pipeline drugs in the field of Fanconi Anemia research. The report encompasses detailed profiles of the pipeline drugs for Fanconi Anemia, including information on clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

 

For the Fanconi Anemia emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Fanconi Anemia pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, clinical trial studies conducted for Fanconi Anemia, any NDA approvals obtained for Fanconi Anemia, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

 

To explore more information on the latest breakthroughs in the Fanconi Anemia Pipeline treatment landscape of the report, click here @ Fanconi Anemia Pipeline Outlook

 

Key Takeaways from the Fanconi Anemia Pipeline Report

  • DelveInsight’s Fanconi Anemia Pipeline analysis depicts a robust space with 4+ active players working to develop 4+ pipeline treatment therapies.
  • The leading Fanconi Anemia Companies are working in the market include Rocket Pharmaceuticals, Foresee Pharmaceuticals, Elixirgen, Genethon, Spotlight Therapeutics, and others
  • Promising Fanconi Anemia Pipeline Therapies include Mozafancogene autotemcel, FP-045, and others
  • Mozafancogene autotemcel (formerly RP L102) is a lentiviral vector-based gene therapy, developed by Rocket Pharmaceuticals for the treatment of Fanconi’s. Currently, it is in Phase II stage of clinical trial evaluation.
  • FP-045 is a potent and highly selective aldehyde dehydrogenase (ALDH2) activator, highly soluble and orally available. ALDH2 is a key mitochondrial regulator of toxic aldehyde metabolism. FP-045 has successfully completed single and multiple ascending dose Phase 1 studies. In vitro, FP-045 increases ALDH2 activity in FANCA-deficient cells and protects FANCA-deficient cells from damage due to exposure to toxic reactive aldehyde such as 4-HNE. FP-045 also decreases TNF-α release from cultured FA lymphocytes. These data support that ALDH2 activity may be important in maintaining the development of blood cells in Fanconi anemia patients and as such may be a useful treatment for patients with incipient bone marrow failure.

 

Fanconi Anemia Overview

Fanconi anemia (FA) is a rare genetic disorder, involving all three blood cell lines. It is the most common cause of inherited bone marrow failure characterized by pancytopenia. Additionally, it affects almost all organs of the body. Fanconi anemia is mainly based upon the molecular mechanism involving a defective homologous recombination DNA repair pathway, defects in proteins as well as other enzymes involved in the repair of damaged DNA following various alkylating agents, irradiation, and cytotoxic drugs.

 

For further information, refer to the detailed Fanconi Anemia Unmet Needs, Fanconi Anemia Market Drivers, and Fanconi Anemia Market Barriers, click here for Fanconi Anemia Ongoing Clinical Trial Analysis

 

Fanconi Anemia Emerging Drugs Profile

  • Mozafancogene autotemcel: Rocket Pharmaceuticals
  • FP-045: Foresee Pharmaceuticals

 

Fanconi Anemia Pipeline Therapeutics Assessment

There are approx. 4+ key companies which are developing the therapies for Fanconi Anemia. The companies which have their Fanconi Anemia drug candidates in the most advanced stage, i.e. phase II include, Rocket Pharmaceuticals.

 

Request a sample and discover the recent advances in Fanconi Anemia Ongoing Clinical Trial Analysis and Medications, click here @ Fanconi Anemia Treatment Landscape

 

Fanconi Anemia Pipeline Therapeutics Assessment

• Fanconi Anemia Assessment by Product Type

• Fanconi Anemia by Stage and Product Type

• Fanconi Anemia Assessment by Route of Administration

• Fanconi Anemia by Stage and Route of Administration

• Fanconi Anemia Assessment by Molecule Type

• Fanconi Anemia by Stage and Molecule Type

 

Some of the Companies in the Fanconi Anemia Therapeutics Market include-

Rocket Pharmaceuticals, Foresee Pharmaceuticals, Elixirgen, Genethon, Spotlight Therapeutics, and others

 

Dive deep into rich insights for drugs for Fanconi Anemia Pipeline, click here @ Fanconi Anemia Unmet Needs and Analyst Views

 

Scope of the Fanconi Anemia Pipeline Report

  • Coverage- Global
  • Fanconi Anemia Companies- Rocket Pharmaceuticals, Foresee Pharmaceuticals, Elixirgen, Genethon, Spotlight Therapeutics, and others
  • Fanconi Anemia Pipeline Therapies- Mozafancogene autotemcel, FP-045, and others.
  • Fanconi Anemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Fanconi Anemia Mergers and acquisitions, Fanconi Anemia Licensing Activities @ Fanconi Anemia Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Fanconi Anemia Executive Summary
  3. Fanconi Anemia: Overview
  4. Fanconi Anemia Pipeline Therapeutics
  5. Fanconi Anemia Therapeutic Assessment
  6. Fanconi Anemia – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Mozafancogene autotemcel: Rocket Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. FP-045: Foresee Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Fanconi Anemia Key Companies
  21. Fanconi Anemia Key Products
  22. Fanconi Anemia- Unmet Needs
  23. Fanconi Anemia- Market Drivers and Barriers
  24. Fanconi Anemia- Future Perspectives and Conclusion
  25. Fanconi Anemia Analyst Views
  26. Fanconi Anemia Key Companies
  27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services